![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SOCS1 |
Gene summary for SOCS1 |
![]() |
Gene information | Species | Human | Gene symbol | SOCS1 | Gene ID | 8651 |
Gene name | suppressor of cytokine signaling 1 | |
Gene Alias | AISIMD | |
Cytomap | 16p13.13 | |
Gene Type | protein-coding | GO ID | GO:0001101 | UniProtAcc | O15524 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
8651 | SOCS1 | HSIL_HPV_2 | Human | Cervix | HSIL_HPV | 5.25e-12 | -4.36e-01 | 0.0208 |
8651 | SOCS1 | CCI_1 | Human | Cervix | CC | 2.11e-03 | -5.07e-01 | 0.528 |
8651 | SOCS1 | CCI_3 | Human | Cervix | CC | 3.48e-02 | -4.75e-01 | 0.516 |
8651 | SOCS1 | CCII_1 | Human | Cervix | CC | 6.78e-08 | -5.07e-01 | 0.3249 |
8651 | SOCS1 | Tumor | Human | Cervix | CC | 2.18e-05 | -3.40e-01 | 0.1241 |
8651 | SOCS1 | sample3 | Human | Cervix | CC | 2.38e-05 | -2.86e-01 | 0.1387 |
8651 | SOCS1 | H2 | Human | Cervix | HSIL_HPV | 2.42e-06 | -3.73e-01 | 0.0632 |
8651 | SOCS1 | L1 | Human | Cervix | CC | 2.31e-06 | -4.93e-01 | 0.0802 |
8651 | SOCS1 | T3 | Human | Cervix | CC | 2.02e-04 | -3.06e-01 | 0.1389 |
8651 | SOCS1 | LZE20T | Human | Esophagus | ESCC | 2.84e-14 | 7.87e-01 | 0.0662 |
8651 | SOCS1 | LZE22T | Human | Esophagus | ESCC | 5.53e-04 | 7.45e-01 | 0.068 |
8651 | SOCS1 | LZE24T | Human | Esophagus | ESCC | 1.18e-12 | 5.14e-01 | 0.0596 |
8651 | SOCS1 | LZE21T | Human | Esophagus | ESCC | 1.72e-06 | 9.04e-01 | 0.0655 |
8651 | SOCS1 | P1T-E | Human | Esophagus | ESCC | 1.43e-15 | 1.70e+00 | 0.0875 |
8651 | SOCS1 | P2T-E | Human | Esophagus | ESCC | 2.54e-85 | 1.65e+00 | 0.1177 |
8651 | SOCS1 | P4T-E | Human | Esophagus | ESCC | 3.74e-53 | 1.54e+00 | 0.1323 |
8651 | SOCS1 | P5T-E | Human | Esophagus | ESCC | 7.79e-40 | 1.03e+00 | 0.1327 |
8651 | SOCS1 | P8T-E | Human | Esophagus | ESCC | 1.74e-07 | 4.17e-01 | 0.0889 |
8651 | SOCS1 | P9T-E | Human | Esophagus | ESCC | 5.40e-16 | 5.92e-01 | 0.1131 |
8651 | SOCS1 | P10T-E | Human | Esophagus | ESCC | 7.06e-33 | 7.21e-01 | 0.116 |
Page: 1 2 3 4 5 6 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00508681 | Oral cavity | EOLP | negative regulation of T cell activation | 28/2218 | 122/18723 | 4.03e-04 | 3.58e-03 | 28 |
GO:0043550 | Oral cavity | EOLP | regulation of lipid kinase activity | 19/2218 | 71/18723 | 4.53e-04 | 3.99e-03 | 19 |
GO:0046638 | Oral cavity | EOLP | positive regulation of alpha-beta T cell differentiation | 15/2218 | 50/18723 | 4.75e-04 | 4.16e-03 | 15 |
GO:0046636 | Oral cavity | EOLP | negative regulation of alpha-beta T cell activation | 13/2218 | 43/18723 | 1.03e-03 | 7.63e-03 | 13 |
GO:00182121 | Oral cavity | EOLP | peptidyl-tyrosine modification | 65/2218 | 378/18723 | 1.25e-03 | 9.02e-03 | 65 |
GO:20005161 | Oral cavity | EOLP | positive regulation of CD4-positive, alpha-beta T cell activation | 12/2218 | 39/18723 | 1.34e-03 | 9.33e-03 | 12 |
GO:00603304 | Oral cavity | EOLP | regulation of response to interferon-gamma | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:00603344 | Oral cavity | EOLP | regulation of interferon-gamma-mediated signaling pathway | 7/2218 | 16/18723 | 1.40e-03 | 9.58e-03 | 7 |
GO:00456203 | Oral cavity | EOLP | negative regulation of lymphocyte differentiation | 15/2218 | 55/18723 | 1.42e-03 | 9.62e-03 | 15 |
GO:00507301 | Oral cavity | EOLP | regulation of peptidyl-tyrosine phosphorylation | 48/2218 | 264/18723 | 1.61e-03 | 1.08e-02 | 48 |
GO:00181081 | Oral cavity | EOLP | peptidyl-tyrosine phosphorylation | 64/2218 | 375/18723 | 1.65e-03 | 1.09e-02 | 64 |
GO:0046639 | Oral cavity | EOLP | negative regulation of alpha-beta T cell differentiation | 9/2218 | 26/18723 | 2.14e-03 | 1.34e-02 | 9 |
GO:0042532 | Oral cavity | EOLP | negative regulation of tyrosine phosphorylation of STAT protein | 7/2218 | 17/18723 | 2.14e-03 | 1.34e-02 | 7 |
GO:00456212 | Oral cavity | EOLP | positive regulation of lymphocyte differentiation | 23/2218 | 104/18723 | 2.14e-03 | 1.34e-02 | 23 |
GO:00455811 | Oral cavity | EOLP | negative regulation of T cell differentiation | 13/2218 | 47/18723 | 2.52e-03 | 1.53e-02 | 13 |
GO:004544415 | Oral cavity | EOLP | fat cell differentiation | 42/2218 | 229/18723 | 2.58e-03 | 1.56e-02 | 42 |
GO:0043374 | Oral cavity | EOLP | CD8-positive, alpha-beta T cell differentiation | 6/2218 | 14/18723 | 3.54e-03 | 2.01e-02 | 6 |
GO:00455822 | Oral cavity | EOLP | positive regulation of T cell differentiation | 20/2218 | 91/18723 | 4.35e-03 | 2.37e-02 | 20 |
GO:20011851 | Oral cavity | EOLP | regulation of CD8-positive, alpha-beta T cell activation | 7/2218 | 19/18723 | 4.48e-03 | 2.42e-02 | 7 |
GO:00466271 | Oral cavity | EOLP | negative regulation of insulin receptor signaling pathway | 10/2218 | 35/18723 | 5.99e-03 | 3.00e-02 | 10 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0412014 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0514514 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
hsa049172 | Cervix | CC | Prolactin signaling pathway | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa0412015 | Cervix | CC | Ubiquitin mediated proteolysis | 49/1267 | 142/8465 | 4.26e-09 | 7.68e-08 | 4.54e-08 | 49 |
hsa0514515 | Cervix | CC | Toxoplasmosis | 34/1267 | 112/8465 | 2.42e-05 | 1.82e-04 | 1.08e-04 | 34 |
hsa0491711 | Cervix | CC | Prolactin signaling pathway | 18/1267 | 70/8465 | 1.29e-02 | 3.87e-02 | 2.29e-02 | 18 |
hsa0514522 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
hsa0514532 | Cervix | HSIL_HPV | Toxoplasmosis | 22/459 | 112/8465 | 1.07e-07 | 3.14e-06 | 2.54e-06 | 22 |
hsa0412027 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa0514525 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa049109 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0412036 | Esophagus | ESCC | Ubiquitin mediated proteolysis | 122/4205 | 142/8465 | 6.53e-20 | 7.29e-18 | 3.74e-18 | 122 |
hsa05145111 | Esophagus | ESCC | Toxoplasmosis | 76/4205 | 112/8465 | 6.83e-05 | 2.90e-04 | 1.48e-04 | 76 |
hsa0491014 | Esophagus | ESCC | Insulin signaling pathway | 89/4205 | 137/8465 | 1.97e-04 | 7.32e-04 | 3.75e-04 | 89 |
hsa0412041 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0491041 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
hsa0514521 | Liver | HCC | Toxoplasmosis | 70/4020 | 112/8465 | 9.25e-04 | 3.52e-03 | 1.96e-03 | 70 |
hsa04917 | Liver | HCC | Prolactin signaling pathway | 43/4020 | 70/8465 | 1.30e-02 | 3.19e-02 | 1.78e-02 | 43 |
hsa0412051 | Liver | HCC | Ubiquitin mediated proteolysis | 110/4020 | 142/8465 | 1.67e-13 | 3.74e-12 | 2.08e-12 | 110 |
hsa0491051 | Liver | HCC | Insulin signaling pathway | 95/4020 | 137/8465 | 1.53e-07 | 1.97e-06 | 1.10e-06 | 95 |
Page: 1 2 3 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SOCS1 | SNV | Missense_Mutation | c.445G>A | p.Glu149Lys | p.E149K | O15524 | protein_coding | tolerated(1) | benign(0.001) | TCGA-AD-6895-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD | |
SOCS1 | SNV | Missense_Mutation | c.467C>T | p.Ala156Val | p.A156V | O15524 | protein_coding | tolerated(0.25) | benign(0.042) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
SOCS1 | deletion | Frame_Shift_Del | novel | c.586delN | p.Leu196SerfsTer9 | p.L196Sfs*9 | O15524 | protein_coding | TCGA-AA-3877-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
SOCS1 | SNV | Missense_Mutation | novel | c.581N>C | p.Ile194Thr | p.I194T | O15524 | protein_coding | deleterious(0) | benign(0.143) | TCGA-AP-A059-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SOCS1 | SNV | Missense_Mutation | novel | c.601N>T | p.Arg201Cys | p.R201C | O15524 | protein_coding | deleterious(0) | probably_damaging(0.939) | TCGA-DF-A2KN-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | Unknown | I/II | Unknown | Unknown | SD |
SOCS1 | SNV | Missense_Mutation | novel | c.329A>T | p.Asn110Ile | p.N110I | O15524 | protein_coding | deleterious(0) | probably_damaging(0.953) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SOCS1 | SNV | Missense_Mutation | novel | c.370N>G | p.Thr124Ala | p.T124A | O15524 | protein_coding | tolerated(0.18) | possibly_damaging(0.525) | TCGA-EO-A3B0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
SOCS1 | deletion | Frame_Shift_Del | novel | c.594delC | p.Val199SerfsTer6 | p.V199Sfs*6 | O15524 | protein_coding | TCGA-DI-A1BU-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | paclitaxel | SD | ||
SOCS1 | SNV | Missense_Mutation | novel | c.271G>A | p.Glu91Lys | p.E91K | O15524 | protein_coding | tolerated(0.47) | benign(0.112) | TCGA-IQ-A61H-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
SOCS1 | SNV | Missense_Mutation | c.379N>T | p.Arg127Cys | p.R127C | O15524 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CG-5721-01 | Stomach | stomach adenocarcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
8651 | SOCS1 | CLINICALLY ACTIONABLE, KINASE | INSULIN | INSULIN | 18171911 | |
8651 | SOCS1 | CLINICALLY ACTIONABLE, KINASE | IL-2 | ALDESLEUKIN | 12928391 |
Page: 1 |